Pay in 4 interest-free payments of $7.01 Learn more
Ships within 48 hours · Estimated delivery Oct 11 - Oct 16
BPC-157 builds the new microvasculature, TB-500 mobilizes the cells that use it
The harsh environment of your digestive system often breaks down the glutathione molecule before it can reach your cells and exert its beneficial effects
Back in 2018, most of its earnings came from generics, with only a small share driven by innovation. Between 2025 and 2027, the company expects to bring dozens of major breakthroughs to market from GLP-1 therapies for obesity and diabetes to next-generation oncology treatments. Source: *Opinions are my own To view or add a comment, sign in Big Pharma News: Pfizer is set to acquire Metsera in a deal worth up to $4.9B Why it matters: $47.50/share upfront + $22.50/share tied to milestones Lead candidate MET-097i (GLP-1 therapy) showed 11.3% weight loss in 12 weeks Pipeline includes monthly amylin-based injections + oral obesity drugs Puts Pfizer head-to-head with Lilly & Novo Nordisk in the obesity race This move highlights the booming obesity drug market and pharmas growing appetite for metabolic innovation
Los catlogos mejor valorados incluyen tragamonedas con alto retorno terico, mesas de ruleta y blackjack con reglas transparentes, y juegos en vivo con crupieres profesionales que fomentan la inmersin
Noyan-AshrafMHMomenMABanKSadiAMZhouYQRiaziAMet al
